APPLICATION
Application Note
The peptide is used for blocking the activity of RAIDD (CT) (GTX28425). Incubatingthe peptide with equal volume of antibody for 30 min at 37ºC usually completely blocks theantibody activity in Western blotting.
PROPERTIES
Form
Liquid
Buffer
PBS, 0.1% BSA
Preservative
0.02% Sodium azide
Storage
Store the peptide at -20ºC, stable for one year.
Concentration
0.20 mg/ml (Please refer to the vial label for the specific concentration.)
Conjugation
Unconjugated
Note
For laboratory research use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
Purchasers shall not, and agree not to enable third parties to, analyze, copy, reverse engineer or otherwise attempt to determine the structure or sequence of the product.
TARGET
Synonyms
Casp2 And Ripk1 Domain Containing Adaptor With Death Domain , Mrt34 , Raidd , Cradd
Background
Apoptosis, or programmed cell death, occurs during normal cellular differentiation and development of multicellular organisms. Apoptosis is induced by certain cytokines including TNF and Fas ligand of the TNFfamily through their death domain (DD) containing receptors, TNFR1 and Fas. The death signals are transduced by a group of DD containing adapter molecules. A novel cell death adapter was recently identified by two independent groups and designated RAIDD (RIP associated ICH1/CED3 homologous protein with DD) and CRADD (caspase and RIP adapter with DD). RAIDD contains a DD and a CARD (for caspase recruitment domain) which interact with RIP and caspase, respectively, to transduce death signals. RAIDD is constitutively expressed in many tissues and mediates apoptosis caused by Fas and TNFR1.
Research Area
REFERENCE
There are currently no references for RAIDD peptide (GTX28461). Be the first to share your publications with this product.
REVIEW
There are currently no reviews for RAIDD peptide (GTX28461). Be the first to share your experience with this product.